Here are the Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Cost of fenofibrate cap 134mg, cost effectiveness synonyms, cost effectiveness of fenofibrate for weight, cost effectiveness of modular over stick built, cost effectiveness meaning, cost effectiveness definition, cost effectiveness of fenofibrate for preventing alzheimer s, cost effectiveness of fenofibrate for cholesterol.
Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia
Background: This study investigated the cost-effectiveness of using fenofibrate to treat type 2 diabetes in Australia. The financial burden of type 2 diabetes mellitus is estimated to surpass AUD10 billion, mainly due to the cost of diabetic complications from diabetic neuropathy. Clinical evidence from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study demonstrated that fenofibrate can reduce the risk of amputation and other diabetes-related complications.
Methods: This study used a calibrated UKPDS model with an Australian diabetes cohort to simulate complications and deaths over a 20-year time horizon. The effectiveness of fenofibrate was assessed using the FIELD study. Total cost was calculated over the 20-year time horizon. Input data was obtained from the Australian Refined-Disease Related Groups and the Australian Pharmaceutical Benefits Scheme.
Results: The model estimated that fenofibrate is associated with lower complication costs, which save over AUD 4.6 million per 1,000 patients. The most significant savings were observed in amputations. The incremental cost-effectiveness ratio for fenofibrate treatment was estimated to be AUD 739/LY gained and AUD 1189/QALY gained.
Conclusion: The use of fenofibrate in Type 2 diabetes patients is estimated to result in cost savings in an Australian setting due to fewer diabetes complications. © The Author(s) 2024.
Authors : Kim H.; Lyu J.; Raja V.; Kim K.
Source : BioMed Central Ltd
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1186/s12962-024-00591-8 |
| ISSN | 14787547 |
| Volume | 22 |
You can download the article here
If You have any problem, contact us here